Content
September 2017, Volume 1, Issue 3
- 149-165 Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
by Spyros Kolovos & Judith E. Bosmans & Heleen Riper & Karine Chevreul & Veerle M. H. Coupé & Maurits W. Tulder - 167-173 Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - 175-184 Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial
by Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind - 185-194 Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications
by Charles C. Ezenduka & Daniel Resende Falleiros & Brian B. Godman - 195-202 Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
by Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota - 203-221 Health System Efficiency: A Fragmented Picture Based on OECD Data
by Andreas Behr & Katja Theune - 223-229 Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
by Astrid Darsonval & Virginie Besson & Claire Cavalin
June 2017, Volume 1, Issue 2
- 73-77 Model Registration: A Call to Action
by Christopher James Sampson & Tim Wrightson - 79-97 Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio - 99-108 Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
by Eva Kaltenthaler & Christopher Carroll & Daniel Hill-McManus & Alison Scope & Michael Holmes & Stephen Rice & Micah Rose & Paul Tappenden & Nerys Woolacott - 109-115 A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens
by Victoria L. Phillips & Anwar L. Byrd & Saira Adeel & Limin Peng & Dawn D. Smiley & Guillermo E. Umpierrez - 117-121 Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas
by Marios-Nikolaos Kouskoukis & Charalambos Botsaris - 123-131 Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
by Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo - 133-141 Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes
by Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers - 143-143 Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio
March 2017, Volume 1, Issue 1
- 1-12 The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
by Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas - 13-23 Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
by Jeff Richardson & Angelo Iezzi & Gang Chen & Aimee Maxwell - 25-36 Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
by Jameel Nazir & Malin Berling & Charles McCrea & Francis Fatoye & Sally Bowditch & Zalmai Hakimi & Adrian Wagg - 37-51 Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
by Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer - 53-63 A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
by Eric C. Leuthardt & Jeff Voigt & Albert H. Kim & Pete Sylvester - 65-68 Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
by Ilke Akpinar & Philip Jacobs & Tien Dat Tran - 69-70 Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
by Przemysław Holko - 71-71 Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
by Ilke Akpinar & Philip Jacobs & Dat T. Tran
Printed from https://ideas.repec.org/s/spr/pharmo4.html